Key facts
- This page summarizes Pierre Beaurang's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Aug 2021, 18:20.
Pierre Beaurang - 10 Aug 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- NRIX
- Reported as of
- 10 Aug 2021
- Net transaction value
- -$215,601
- SEC form
- 4
- Accepted by SEC
- 11 Aug 2021, 18:20:52 UTC
- Prior SEC filing
- 12 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Ring, as Attorney-in-Fact for Pierre Beaurang
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Pierre Beaurang filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 11 Aug 2021.
Change
- Previous filing in this sequence was filed on 12 Jul 2021.
- Current net transaction value: -$215,601.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRIX
transaction
Common Stock
Options Exercise
- Transaction value
- $8,325
- Shares
- +7,500
- Change %
- +173%
- Price
- $1.11*
- Shares after
- 11,830
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
NRIX
transaction
Common Stock
Sale
- Transaction value
- -$167,129
- Shares
- -5,620
- Change %
- -48%
- Price
- $29.74
- Shares after
- 6,210
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
NRIX
transaction
Common Stock
Sale
- Transaction value
- -$56,797
- Shares
- -1,880
- Change %
- -30%
- Price
- $30.21
- Shares after
- 4,330
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F3
NRIX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 116,666
- Date
- 10 Aug 2021
- Ownership
- By Trust
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRIX
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,500
- Change %
- -53%
- Price
- $0.000000
- Shares after
- 6,562
- Date
- 10 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $1.11
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Footnote F2
Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
Footnote F3
Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34.
Footnote F4
The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Footnote F5
The option is fully vested.